July 19th, 2011

Johnson & Johnson and “Our Global Giving”

Sharon D’Agostino, Vice President, Worldwide Corporate Contributions & Community Relations, visiting the AED Girls Education program that Johnson & Johnson supports in Dar es Salaam, Tanzania.

From Sharon D’Agostino, Vice President, Worldwide Corporate Contributions and Community Relations, Johnson & Johnson

Johnson & Johnson has a long tradition of Corporate Giving that is inspired by Our Credo responsibility to communities around the world.  Each year we publish “Our Global Giving,” an annual report that showcases the philanthropic work our Company does, working closely with our community-based partners.  The report also highlights the work of Johnson & Johnson colleagues who share the goal of making life-changing, long-term differences in human health. 

In 2010, we supported nearly 700 programs in more than 50 countries, and while these numbers underscore our commitment to local solutions for improving health, they do not capture the many, many personal stories of those who do this work and those who are touched by it.  I am fortunate and grateful to meet some of these people and am always deeply moved by these visits. 

“Our Global Giving” celebrates all of our partners, and though it is not possible to highlight the work of all programs, we have captured examples that provide a representation of the breadth of programs across our three focus areas — saving and improving the lives of women and children, building the skills of people who serve community health needs, and preventing disease and reducing stigma. 

Read More

July 15th, 2011

The Evolution of Social Media: EVO 2011 Conference

From Susan Can, Director, Corporate Equity, Johnson & Johnson Global Marketing Group

On the weekend of July 7th, I had the pleasure of attending the EVO conference where Johnson & Johnson was one of the corporate sponsors.   Set in the scenic mountains of Park City, Utah, this was an amazing experience for us. We were able to meet and talk with so many people who are making a difference in the world by harnessing the power of the internet.

While many bloggers at the conference cover topics related to home, family and health, many also cover topics related to using social media for social good: using the power of the internet to champion specific causes to make a difference.  We were there to engage with attendees on this shared topic of interest – using, “Social Media for Social Good.” 

Visitors to the Johnson & Johnson suite were introduced to three varied aspects of what is happening in the world of social media and Johnson & Johnson.  We introduced &you™ (a brand new digital tool for social good – more on that below).  Participants were able to learn about specific causes that Johnson & Johnson supports, as well as given an opportunity to share their story on how they use social media for social good.

Read More

July 14th, 2011

Healthy Future 2015

From Patrick McCrummen, Senior Director, Corporate Citizenship, Johnson & Johnson

There was an interesting piece last month by Carl Cannon of RealClearPolitics on the evolution of corporate social responsibility (CSR). In the article, Cannon highlights the different views on corporate social responsibility that have developed over the years, including Milton Friedman’s well known rebuttal to the idea of CSR 40 years ago in which he said, “Only people can have responsibilities.  Businesses as a whole cannot be said to have responsibilities, even in this vague sense.”  At the conclusion of the piece, Cannon posits, “Friedman may have had it backwards.  Yes, individuals and not businesses – have responsibilities.  But businesses are run by people.”

Many who know the familiar red script of our logo also know that we have incorporated CSR into our business strategy for decades. In 1943, our then Chairman Robert Wood Johnson established Our Credo, a set of guiding principles and business values for Johnson & Johnson, which sets forth our responsibilities to the stakeholders we serve — our customers, employees, communities and shareholders. 

Even back then, before CSR or sustainability were mainstream ideas, the Credo addressed our responsibility to communities to “be good citizens –support good works and charities and bear our fair share of taxes. 

Read More

July 11th, 2011

Using Innovation to Meet Health Care Needs in Asia

From Michael del Prado, Company Group Chairman, Medical Devices & Diagnostics, Asia-Pacific.

The other week, I attended the opening of the Johnson & Johnson Medical Companies Innovation Center in Suzhou, China, our first medical devices and diagnostics innovation center in China and our second in Asia.  The opening of this center comes at a very special time for Johnson & Johnson — during our 125th anniversary year — and it continues one of our oldest traditions as a company:  working to meet unmet health care needs. 

The Asia-Pacific region of the world where I live and work is home to almost 60 percent of the world’s population, but many people in these emerging economies lack access to quality health care.   That’s something we want to help change. 

Johnson & Johnson has been doing business in China, India and other Asian countries for a very long time, first selling our products through local distributors and later opening operating companies in Asia, well ahead of many other multinationals.  We’ve had companies in China since 1982, but access to many of our products centered around the main population centers like Shanghai or Beijing.   The Suzhou Innovation Center will allow us to better serve the millions of men, women and children outside of the main population centers in China who are now gaining access to some degree of healthcare coverage. 

Read More

July 8th, 2011

JNJBTW Follow Friday

As we get ready for the weekend, what better way to spend a summer Friday on JNJBTW than to take a look at what’s going on at the other Johnson & Johnson social media sites.

The 2010 Johnson & Johnson contributions report is out, and is available online at this link.

The featured homepage stories on jnj.com this week are drawn from the contributions report.  Recycling Materials and Shaping Lives follows one of the catadors at The recycling cooperative Futura in São José dos Campos, Brazil.  A catador is a person who lives and works in a cooperative, collecting and processing waste material for recycling.  These cooperatives provide employment, a level of dignity and a purpose-filled way of life for their members, and they are becoming key suppliers of recycled materials to businesses.  Keeping Children Warm and Safe tells the story of some Johnson & Johnson Family of Companies employees and their colleagues who volunteer their time to make blankets for children affected by humanitarian disasters as part of the One Child, One Blanket program. (By the way, employees finding a way to make a personal contribution to help after disasters is a tradition that goes back to 1906 at Johnson & Johnson.) Resuscitation Saves Tens of Thousands of Newborns in China profiles China’s Neonatal Resuscitation Program (NRP), a joint effort by Johnson & Johnson, the Chinese Ministry of Health and the American Academy of Pediatrics to address birth asphyxia—when a baby is unable to breathe at birth.

Read More

June 30th, 2011

Johnson & Johnson Recognized at the 2011 Dosie Awards

From Ray Jordan, Corporate Vice President, Public Affairs and Corporate Communication, Johnson & Johnson

The 2011 Dosie Awards, which aim to highlight some of the best examples of social media in the healthcare industry, were recently announced and I’m proud to say Johnson & Johnson was named Company of the Year in Social Media based on the awards received by many of our social media properties, including: the Johnson & Johnson Network page on Facebook, the Johnson & Johnson health channel on YouTube, the @JNJStories Twitter feed, Diabetes Handprint, Children with Diabetes and the JNJ BTW corporate blog. I wanted to take a moment to congratulate all our J&J team members who drive, challenge and nurture our presence in the social media space.

We’re always focusing on what we can do better, so it’s pretty humbling to receive such honor and praise for our social media work. It has been an interesting journey for all of us here at Johnson & Johnson as we figure out the best ways to join the online conversation about health care. As we continue to participate in and learn about the social media space, we hope to find new and innovative ways to engage with you and earn your respect every day.

Read More

June 29th, 2011

2011 Dr. Paul Janssen Award for Biomedical Research Honors Biotechnology Pioneer

By Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Biotechnology has come a long way since the discovery of recombinant DNA almost 40 years ago and the sequencing of the human genome a decade ago.  Today, the term has a broader definition: biomarkers, antibodies, genomics, protemics, RNA, novel scaffolds, peptides, cell therapies, and more, all to help us solve the most important diseases of our time. One example of such an advance is the treatment of angiogenesis, the process of new blood vessel formation that plays a key role in cancer proliferation and a number of other diseases.  These treatments have improved the lives of millions of patients.

Dr. Napoleone Ferrara, Genentech Fellow, has been influential in the development of anti-angiogenesis treatments. Through the identification of a human vascular endothelial cell growth factor (VEGF), he discovered there may be a ways to control the blood supply to particular parts of the body. His innovative work on angiogenesis opened the door to the development of a new class of therapeutics to combat a serious eye disorder and contributed to the development of new oncology therapeutics.

Today Johnson & Johnson honored Dr. Napoleone Ferrara with the 2011 Dr. Paul Janssen Award for Biomedical Research, an award that recognizes passionate and creative scientists like Dr.

Read More

June 28th, 2011

Response to Recent Coverage in the Financial Times

Today’s Financial Times included a story (subscription required) about Johnson & Johnson’s comprehensive approach to preventing and treating disease. The story contained a number of inaccuracies, which Johnson & Johnson addressed in a letter to the Financial Times editors. Here is what we had to say.

Dear Editor of the Financial Times:

Today’s Financial Times included an article about the comprehensive approach of Johnson & Johnson to the prevention and treatment of significant chronic diseases. The story contained a number of inaccuracies.

While Johnson & Johnson believes the breadth of its business interests across consumer, diagnostics and pharmaceuticals business segments is a valuable advantage in its approach to the treatment of a number of chronic conditions, including cancer, the company does not intend to market consumer and regulated products more closely, as reported. In a discussion with the Financial Times, company executives talked about how leaders from the various business segments share insights that improve their understanding of the needs of patients with cancer and other conditions, and, presumably, result in products and services that better meet these needs. They did not, however, state or suggest that the company would market such products together.


Bill Price
Vice President, Media Relations
Johnson & Johnson

Read More

June 23rd, 2011

Partnering for a Healthier World

From Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

This week, a team from Johnson & Johnson joined other world leaders at the Pacific Health Summit to discuss an important and timely topic: vaccines.

Johnson & Johnson made a commitment to vaccines through its recent acquisition of Crucell N.V., a company that is passionate about innovation and about meeting the public health demand for vaccines for children in the world’s poorest countries.

Crucell specializes in the research and development of innovative vaccines especially for infectious diseases that devastate families in the developing world.  The company has a track-record for innovation and is passionate about delivering high quality and easy to use vaccines consistently, quickly and at the lowest possible prices in developing markets. 

One of their most important products is Quinvaxem® a single-dose, fully-liquid vaccine, developed specifically for use in developing countries. As a pentavalent vaccine, it offers protection against five of the world’s most prevalent childhood diseases– Hepatitis-B, Haemophilus influenzae type B (Hib), Diphtheria, Tetanus and Pertussis. Since its launch, more than 200 million doses have been distributed worldwide, meaning that more than 60 million children in many of the poorest countries in the world have been fully vaccinated. It is becoming the cornerstone of UNICEF’s childhood vaccine program.  

Read More

June 10th, 2011

Advancing the Science at ASCO—Metastatic Prostate Cancer

By Vicki Vakiener, Vice President, Sales & Marketing, Veridex, LLC

Our mission is to care for the world, one patient at a time. As we focus on defeating life-threatening diseases such as cancer, we realize it is our collective knowledge and advanced science that will help us successfully tackle this hefty goal.

Over the past decade, I’ve seen an increase in internal and external collaborations that help us to accelerate the development of novel medicines, diagnostic tools and treatment solutions for patients worldwide. When I can find and apply the best science, I know I’m   delivering on our heritage and serving the patients who rely on our solutions to be healthier, feel better and live longer, everyday.

To that end, I was pleased to see the collaborative efforts of our diagnostic and pharmaceutical teams at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting earlier this week. Together, Ortho Clinical Diagnostics, Inc. and Centocor Ortho Biotech Inc. utilized their expertise to advance the science of metastatic prostate cancer, where there is still an unmet medical need for diagnostic tools and therapies.

While there is still work to be done, I’m pleased at the progress our company has made thus far.

Read More